News

REA Group beat FY26 earnings expectations but signalled softer real estate listings ahead, reflecting weaker property market conditions. The company's profit beat is positive for shareholders, but the forward guidance warning suggests Australian property sentiment is cooling—a key indicator for construction, financial services, and consumer discretionary sectors. Watch for how this impacts the ASX200 property and tech indices, and whether other real estate platforms (Domain Group) follow with similar caution.

Block Inc. (formerly Square) posted better-than-expected earnings and raised its 2026 guidance, driven by strength in Cash App and Square payment services. The company is integrating AI across its software engineering stack, which could improve efficiency and competitive positioning in the fintech space. For Australian investors, this matters as Block has a growing presence in APAC payments; stronger US fundamentals and AI productivity gains could support broader valuations in high-growth fintech stocks, though the ASX has limited direct exposure to Block's primary markets.

News Corp has set an ambitious target of $1 billion EBITDA from Dow Jones by fiscal 2030, signalling confidence in the division's profitability and hinting at further margin expansion ahead. This is significant for Australian investors given News Corp's ASX listing and the Dow Jones' importance as a revenue driver (Wall Street Journal, Barron's, MarketWatch). The target suggests management believes digital subscriptions and financial content can sustain higher margins—a bet on premium content positioning in a competitive media landscape.

SanDisk's revenue guidance came in below analyst consensus, triggering a stock decline. This suggests softer-than-expected demand in the memory storage market, likely reflecting broader weakness in semiconductor cycles or data centre spending. For Australian investors with tech exposure, this signals caution in the semiconductor space—watch for similar misses from other chipmakers and monitor whether this reflects inventory corrections or genuine demand softness.

Block (Square/Cash App operator) reported better-than-expected earnings following a significant workforce reduction of 40%, with management attributing improved operational efficiency and product velocity to AI integration. This reflects a broader tech industry trend of using AI to offset labour costs and accelerate development cycles. For ASX investors, this is noteworthy as a case study in AI-driven restructuring that's actually delivering results rather than just cutting costs—though longer-term sustainability depends on whether revenue growth accompanies the margin improvements.

Elon Musk's public commitment to using Nvidia chips exclusively for SpaceX's AI infrastructure is a significant endorsement from one of the world's highest-profile tech leaders. This reinforces Nvidia's dominant position in the AI chip market and validates its dominance in a sector seeing explosive demand. For Australian investors, this matters because Nvidia is a major US tech holding in most portfolio indices, and continued validation of its market position supports the ongoing AI infrastructure boom—though the statement is primarily marketing value rather than a binding commercial contract of disclosed size.

MercadoLibre posted a strong 50% YoY revenue jump in Q2, with fintech monthly active users climbing to 88 million—a sign that its digital payments push is gaining real traction across Latin America. The company is showing the growth trajectory investors want to see post-pandemic, though the broader question is whether this pace can sustain as retail spending normalises. Australian investors with LatAm exposure or holding MELI should monitor whether this momentum holds into H2, as fintech adoption in emerging markets remains volatile.

SpaceX's earnings guidance suggests the company plans to offer wireless services using satellite technology, bypassing traditional telecom infrastructure. This threatens the competitive moat of AT&T, Verizon, and T-Mobile, which rely on expensive ground networks—hence the sell-off. For Australian investors, this signals longer-term disruption in telecom, though Telstra, Optus and Vodafone remain less exposed given Australia's geography and regulatory framework. The real threat emerges if SpaceX's satellite broadband actually delivers reliable, low-cost mobile coverage at scale.

SolarEdge Technologies has seen its stock plunge roughly 25% following a revenue guidance miss, with weakness in European markets cited as the primary culprit—offsetting any gains from AI-related developments. This matters because SolarEdge is a major player in solar inverters and energy management, and European softness signals broader headwinds in the renewable energy transition, particularly as subsidies or demand dynamics shift. Australian investors should watch whether this indicates a slowdown in global solar capex spending, which could ripple through local renewable energy and infrastructure stocks.

AstraZeneca's apparent abandonment of preliminary takeover talks with Bristol Myers Squibb has created volatility in both stocks, with AZN initially dropping 9% on deal speculation before recovering on reports the discussions have ceased. The lack of clarity from either company about whether talks were serious or exploratory leaves shareholders and markets guessing about strategic direction and deal likelihood. Australian investors holding pharma exposure should monitor both companies' next earnings calls and formal statements for clarity on M&A intentions and pipeline strategy, as large pharmaceutical consolidation can materially affect sector valuations and competition dynamics.

Novo Nordisk, which revolutionized the GLP-1 weight-loss drug market with Ozempic and Wegovy, has lost market leadership to US rival Eli Lilly. The Danish pharma giant faces competitive pressure from Lilly's Mounjaro (tirzepatide) which is proving more effective and popular, partly due to supply constraints and manufacturing challenges at Novo. This shift has material implications for Novo's growth trajectory and profitability—GLP-1 drugs represent its highest-margin revenue streams. For Australian investors, Novo Nordisk is a significant healthcare holding via local superannuation and managed funds; weakening competitive position could pressure share performance, though the broader GLP-1 market remains massive and growing globally.

AMD reported earnings that failed to excite the market despite meeting expectations, with the key disappointment being guidance on profit margins—a critical metric for semiconductor firms. The stock weakness reflects a broader pattern where investors are pricing in slowing AI demand and tighter profitability across the chip sector. For Australian investors, this matters because AMD is a major portfolio holding in many tech-heavy ETFs, and semiconductor weakness can signal broader tech and growth concerns that ripple through the ASX 200.

Uber beat Q2 profit expectations and reported strong growth in rides and food deliveries, suggesting resilient consumer spending despite economic headwinds. However, the share price decline despite earnings growth suggests investors are either pricing in higher expectations or concerned about forward guidance—watch for commentary on margin pressures and competitive intensity. For Australian investors, Uber's performance is a bellwether for consumer discretionary spending and gig economy health in developed markets.

Eli Lilly reported a 48% revenue increase driven by stronger-than-expected demand for its GLP-1 drugs Mounjaro and Zepbound, signalling continued market growth in the obesity and diabetes treatment space. This result underscores the blockbuster potential of GLP-1 therapeutics and validates the sector's expansion beyond initial forecasts, though it also highlights intense competition as other pharma players like Novo Nordisk scale similar offerings. For Australian investors, this strengthens the outlook for healthcare and pharmaceutical stocks, particularly those with exposure to metabolic disease treatments, and may influence how the ASX's healthcare sector performs relative to broader markets.

Eli Lilly delivered a strong earnings beat with $23B in revenue, driven by surging demand for its GLP-1 drugs Mounjaro (diabetes) and Zepbound (weight loss), which collectively saw volume grow 60% year-on-year. This result reflects the ongoing blockbuster momentum in the obesity and diabetes treatment class, where Lilly competes with Novo Nordisk—a competitive dynamic that's reshaping pharma valuations globally. For Australian investors, this signals sustained strength in the obesity-drug sector and validates the broader healthcare opportunity, though it also highlights Lilly's execution risk if demand eventually normalises.

CVS Health beat Q2 earnings expectations and raised its full-year 2026 guidance, signalling operational resilience in the US healthcare and pharmacy sector. This is positive for the broader healthcare space, though CVS is primarily US-listed and has limited direct ASX exposure. Australian investors with exposure to US healthcare or pharmacy benefit managers via ETFs or direct holdings should note the positive momentum, though the real earnings power and margin sustainability will depend on detailed commentary around PBM margins, which have faced regulatory scrutiny.

Endeavour Group, Australia's second-largest retailer, has written down $311m in assets and reported a significant profit decline, signalling operational stress across its Dan Murphy's and BWS liquor brands and broader retail division. The asset write-down typically reflects management's reassessment of store or asset values amid weaker trading conditions—a red flag for retail fundamentals. For ASX investors, this highlights consumer spending weakness in discretionary categories and raises questions about earnings sustainability, though the 'business reset' commentary suggests management is taking action; watch FY24 guidance and same-store sales trends closely.

Lime has issued forward guidance projecting $1.04B–$1.1B in 2026 revenue with adjusted EBITDA of $265M–$285M, signalling confidence in profitability as the e-scooter company strengthens its balance sheet post-IPO. The outlook suggests the company is trending toward sustainable operations after years of heavy losses, though these are management targets rather than guaranteed results. Australian investors should note micromobility is an emerging but niche sector; the key takeaway is whether Lime can convert scale into real profitability—watch quarterly results and unit economics in coming quarters.

Westgold Resources has announced a major expansion at its Cue Hub, signalling management confidence in the operation's economics and gold market outlook. This capex commitment should support production growth and potentially improve unit costs over the medium term, though execution risk remains. For ASX investors, this demonstrates domestic gold producer resilience and represents a positive signal for the broader materials sector—worth monitoring for FY guidance updates and quarterly production numbers.

Monadelphous Group has secured a significant construction contract from BHP at Nelson's Point, a major project win that should boost the company's revenue pipeline and earnings visibility. For Australian investors, this is material news for MND as it demonstrates strong demand for local engineering services in the resources sector and validates the company's competitive position. Watch for updates on contract size, timeline, and margin expectations in upcoming investor updates, plus any flow-on work from BHP's broader capital program.